Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
Open Access
- 30 July 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 200
Abstract
Background Little is known about tumor-associated vasogenic edema in brain metastasis, yet it causes significant morbidity and mortality. Our purpose was to characterize edema in patients treated with anti-PD-1 and to study potential causes of vessel leakage in humans and in pre-clinical models. Methods We analyzed tumor and edema volume in 18 non-small cell lung (NSCLC) and 18 melanoma patients with untreated brain metastases treated with pembrolizumab on a phase II clinical trial. Melanoma brain metastases were stained with anti-CD34 to assess vessel density and its association with edema. We employed an in vitro model of the blood-brain barrier using short-term cultures from melanoma brain and extracranial metastases to determine tight junction resistance as a measure of vessel leakiness. Results Edema volumes are similar in NSCLC and melanoma brain metastases. While larger tumors tended to have more edema, the correlation was weak (R2 = 0.30). Patients responding to pembrolizumab had concurrent shrinkage of edema volume and vice versa (R2 = 0.81). Vessel density was independent of the degree of edema (R2 = 0.037). Melanoma brain metastasis cells in culture caused loss of tight junction resistance in an in vitro blood-brain barrier model system in some cases, whereas extracerebral cell cultures did not. Conclusions Edema itself should not preclude using anti-PD-1 with caution, as sensitive tumors have resultant decreases in edema, and anti-PD-1 itself does not exacerbate edema in sensitive tumors. Additional factors aside from tumor mass effect and vessel density cause perilesional edema. Melanoma cells themselves can cause decline in tight junction resistance in a system void of immune cells, suggesting they secrete factors that cause leakiness, which might be harnessed for pharmacologic targeting in patients with significant perilesional edema.Keywords
Funding Information
- National Institutes of Health (R01 CA158167, K24CA172123, R01 CA166376, P50 CA121974, R01 CA227473)
- National Cancer Institute (R01 CA204002)
- National Center for Advancing Translational Sciences (KL2 TR000140)
- Melanoma Research Alliance (308721)
- American Cancer Society (30157-RSG-16-216-01-TBG)
This publication has 24 references indexed in Scilit:
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainNew England Journal of Medicine, 2018
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyThe Lancet Oncology, 2018
- Review of cancer treatment with immune checkpoint inhibitorsWiener klinische Wochenschrift, 2017
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialThe Lancet Oncology, 2017
- Correlation of Tumor and Peritumoral Edema Volumes with Survival in Patients with Cerebral MetastasesAnticancer Research, 2017
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialThe Lancet Oncology, 2016
- Advances in therapy for melanoma brain metastasesClinics in Dermatology, 2013
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012
- Corticosteroids in brain cancer patients: benefits and pitfallsExpert Review of Clinical Pharmacology, 2011
- The Control of Vascular Integrity by Endothelial Cell Junctions: Molecular Basis and Pathological ImplicationsDevelopmental Cell, 2009